A drug safety evaluation of everolimus in kidney transplantation.
about
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateEnhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin.Adverse events associated with mTOR inhibitors.Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Managing transplant rejection in the elderly: the benefits of less aggressive immunosuppressive regimens.Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q28067598-FB0410A6-84E1-49C5-A067-D9E7E4F0E02BQ34273081-DF23B242-BF27-4A9C-B334-22DD26E3CBFBQ38068519-54735B9B-D91A-4AD9-AD53-13703B1EDE18Q38229930-CBD8DD51-C4CF-4F47-9B94-09BF9096EA0DQ38962103-86A5A4B1-22B9-48D0-8849-908D065B010CQ45078004-07CF1120-366A-4EEA-B2CE-79867546F124Q52874072-99BE403F-7B25-4548-BF4D-13D5D5EA27E5Q58805821-CA5AFA6D-66D0-42E2-9E8A-4F195BE4365B
P2860
A drug safety evaluation of everolimus in kidney transplantation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A drug safety evaluation of everolimus in kidney transplantation.
@en
type
label
A drug safety evaluation of everolimus in kidney transplantation.
@en
prefLabel
A drug safety evaluation of everolimus in kidney transplantation.
@en
P2860
P1476
A drug safety evaluation of everolimus in kidney transplantation
@en
P2093
Hallvard Holdaas
P2860
P304
P356
10.1517/14740338.2012.722993
P407
P577
2012-09-06T00:00:00Z